• Borah Uttam Department of Pharmaceutical Science, Girijananda Chowdhury Institute of Pharmaceutical Science, Azara, Guwahati, India.
  • Dash Biswajit Department of Pharmaceutical Science, Girijananda Chowdhury Institute of Pharmaceutical Science, Azara, Guwahati, India.
  • Dash Suvakanta Department of Pharmaceutical Science, Girijananda Chowdhury Institute of Pharmaceutical Science, Azara, Guwahati, India.



Visceral leishmaniasis, Cutaneous leishmaniasis, Chemotherapy, Antileishmanial drugs


Leishmaniasis is a dismissed vector-borne tropical contamination thought to be an ailment of poor people. It is a standout among the most ignored tropical sickness as far as medication disclosure and improvement. Moved in neediness stricken nations inside Southeast Asia, East Africa, and Latin America, it is likewise endemic in a few Mediterranean nations. The administration of the heterogeneous disorders controlled by parasites having a place with the genus Leishmania is, especially troublesome in created, non-endemic nations attributable to the newness of doctors with clinical side effects, demonstrative conceivable outcomes, and accessible treatment choices. Most antileishmanial medications are very lethal and introduce resistance issues or require hospitalization, being along these lines not sufficient to the field. As of late changes have been accomplished by blend treatment, decreasing the time, and cost of treatment. Regardless, new medications are still direly required. This overview highlights the chemotherapeutic operators against leishmaniasis, their science, method of activity and the component of resistance in the parasite. Future viewpoints in the territory of new hostile to leishmanial sedate targets are likewise specified.



Download data is not yet available.


Papadopoulou B, Kündig C, Singh A, Ouellette M. Drug resistance in Leishmania: Similarities and differences to other organisms. Drug Resist Updat 1998;1(4):266-78.

Natera S, Machuca C, Padrón-Nieves M, Romero A, Díaz E, Ponte- Sucre A. Leishmania spp.: Proficiency of drug-resistant parasites. Int J Antimicrob Agents 2007;29:637-42.

Croft SL, Coombs GH. Leishmaniasis - Current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003;19(11):502-8.

Hazra B, Golenser J, Nechemiya O, Bhattacharya S,Azzam T, DombA, et al. Inhibitory activity of diospyrin derivatives against Leismania major parasites in vitro, Indian J Pharmacol 2002;34:422-7.

Croft SL, Seifert K, Yardley V. Current scenario of drug development for Leishmaniasis. Indian J Med Res 2006;123:399-410.

Davis AJ, Kedzierski L. Recent advances in antileishmanial drug development. Curr Opin Investig Drugs 2005;6(2):163-9.

Markle WH, Makhoul K. Cutaneous leishmaniasis: Recognition and treatment. Am Fam Physician 2004;69(6):1455-60.

Visbal G, Marchán E, Maldonado A, Simoni Z, Navarro M. Synthesis and characterization of platinum-sterol hydrazone complexes with biological activity against Leishmania (L.) Mexicana. J Inorg Biochem 2008;102(3):547-54.

Baginski M, Czub J. Amphotericin B and its new derivatives - Mode of action. Curr Drug Metab 2009;10(5):459-69.

Dogra J. Current therapies for treatment of cutaneous leishmaniasis in India. Infection 1992;20(4):189-91.

Sereno D, Holzmuller P, Lemesre JL. Efficacy of second line drugs on antimonyl-resistant amastigotes of Leishmania infantum. Acta Trop 2000;74(1):25-31.

Leandro C, Campino L. Leishmaniasis: Efflux pumps and chemoresistance. Int J Antimicrob Agents 2003;22(3):352-7.

Jhingran A, Chawla B, Saxena S, Barrett MP, Madhubala R. Paromomycin: Uptake and resistance in Leishmania donovani. Mol Biochem Parasitol 2009;164(2):111-7.

Davidson RN, den Boer M, Ritmeijer K. Paromomycin. Trans R Soc Trop Med Hyg 2009;103(7):653-60.

Simoes-Mattos MJ, Costa TD, Prata JR, Bevilaqua CM, Sidrim JJ, Rocha MF. Evaluation of terbinafine treatment in Leishmania chagasiinfected hamsters (Mesocricetus auratus).Vet Parasitol 2002;103:207-16.

AlrajhiAA, IbrahimEA, DeVol EB, KhairatM, Faris RM,Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002;346(12):891-5.

Gupta L, Talwar A, Nishi, Palne S, Gupta S, Chauhan PM. Synthesis of marine alkaloid: 8,9-dihydrocoscinamide B and its analogues as Novel class of antileishmanial agents. Bioorg Med Chem Lett 2007;17(14):4075-9.

Hornillos V, Saugar JM, de la Torre BG, Andreu D, Rivas L, Acuña AU, et al. Synthesis of 16-mercaptohexadecylphosphocholine, a miltefosine analog with leishmanicidal activity. BioorgMed Chem Lett


Croft SL, Engel J. Miltefosine - Discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 2006;100 Suppl 1:S4-8.

Singh FV, Vatsyayan R, Roy U, Goel A. Arylanthranilodinitriles: A new biaryl class of antileishmanial agents. Bioorg Med Chem Lett 2006;16(10):2734-7.

Tempone AG, Taniwaki NN, Reimão JQ. Antileishmanial activity and ultrastructural alterations of Leishmania (L.) chagasi treated with the calcium channel blocker nimodipine. Parasitol Res 2009;105(2):499-505.

Sampaio RN, Lucas IC, Filho AV. The use of azythromycin and N-methyl glucamine for the treatment of cutaneous Leishmaniasis caused by Leishmania (Leishmania) amazonensis in C57BL6 mice. An Bras Dermatol 2009;84(2):125-8.

Chowdhary SJ, Chowdhary A, Kashaw S. Macrophage targeting: A strategy for leishmaniasis specific delivery. Int J Pharm Pharm Sci


Sahu M, Siddiqui N. A review on biological importance of pyrimidines in the new era. Int J Pharm Pharm Sci 2016;8(5):8-14.



How to Cite

Uttam, B., D. Biswajit, and D. Suvakanta. “CHEMOTHERAPY OF LEISHMANIASIS – A REVIEW”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 6, June 2017, pp. 5-10, doi:10.22159/ajpcr.2017.v10i6.18863.



Review Article(s)

Most read articles by the same author(s)